SIDE-BY-SIDE EVIDENCE
Compare evidence.
Keep the context.
Select 2–3 profiles from the English Library. Class and grade describe evidence and regulatory context, not comparative effectiveness or suitability for an individual.
Choose profilesSIDE-BY-SIDE EVIDENCE VIEW
Compare selected profiles
| Molecule |  Testosterone | Testagen (KEDG) | Human Chorionic Gonadotropin (hCG) |
|---|---|---|---|
| Research Topic | Clinical / Endocrine Pharmacology | Reproductive Endocrinology | Reproductive Endocrinology |
| Pharmacology | Endogenous androgen / prescription androgen medicine | Synthetic KEDG tetrapeptide; preclinical DNA/histone and endocrine research, not testosterone | Placental glycoprotein hormone and LH/hCG-receptor agonist gonadotropin |
| PrimeCore Class | Class AApproved in a bounded context | Class CExperimental / limited evidence | Class AApproved in a bounded context |
| Evidence Grade | Grade AStrong regulatory + clinical evidence | Grade EPreclinical evidence | Grade AStrong regulatory + clinical evidence |
| Evidence boundary | Testosterone is an endogenous androgen and an active ingredient in authorised prescription medicines, but 'Test' does not identify an ester, formulation, strength, manufacturer or authorisation. Cypionate, enanthate, undecanoate, propionate, no-ester formulations and blends are not automatically interchangeable. TRAVERSE found MACE noninferiority for a specific gel in a defined population while other safety signals remained. This evidence does not authenticate catalogue products or support performance use. WADA 2026 prohibits testosterone and its esters at all times. | Testagen is the synthetic KEDG tetrapeptide (Lys-Glu-Asp-Gly), not the Testagen TDS testosterone product studied in NCT02733133. Verified evidence is preclinical: HeLa-cell and DNA/histone experiments and thyroid models in hypophysectomized birds. No human therapeutic trial of exact KEDG was verified in this review; testosterone, fertility, thyroid-treatment and anti-aging benefits and human safety remain unestablished. Exact product authorisation requires verification, and absence from named anti-doping examples is not sport clearance. | A placental glycoprotein hormone with product-specific prescription uses in reproductive medicine and selected endocrine contexts. Urine-derived Pregnyl, recombinant Ovidrel, endogenous hCG and online weight-loss products are not interchangeable; hCG is not FDA-approved for weight loss. |
| Unknowns | Insufficient data in the current dataset | Insufficient data in the current dataset | Insufficient data in the current dataset |
| Limitations |
| Insufficient data in the current dataset | Insufficient data in the current dataset |
| Sources |
|
| |
| Read more | Read English overview | Read English overview | Read English overview |
This table does not compare doses, cross-trial outcomes or individual suitability. Missing information does not establish an absence of risk.
Choose another comparisonContinue reading
Missing fields mean information is unavailable in the current structured dataset, not that a molecule has no risks or uncertainties. English translations retain the original evidence boundaries. Where translation is not yet verified, the original Thai excerpts remain available under an explicit label. Sources retain their original language.
10 questions before drawing conclusions